市場調査レポート
商品コード
1321709

ポイント・オブ・ケア(POC)分子診断薬の世界市場

Point of Care (POC) Molecular Diagnostics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 597 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
ポイント・オブ・ケア(POC)分子診断薬の世界市場
出版日: 2023年08月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 597 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ポイント・オブ・ケア(POC)分子診断薬の世界市場は2030年までに88億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に32億米ドルと予測されたポイント・オブ・ケア(POC)分子診断薬の世界市場は、2030年には88億米ドルに達すると予測され、分析期間2022-2030年のCAGRは13.4%で成長すると予測されます。本レポートで分析されているセグメントの一つであるPCRベースは、CAGR14.4%を記録し、分析期間終了時には57億米ドルに達すると予測されています。現在進行中のパンデミック後の回復を考慮し、遺伝子シークエンシングベースのセグメントの成長は、今後8年間のCAGRを10.7%に修正しました。

米国市場は13億米ドル、中国はCAGR 16.3%で成長すると予測

米国のポイント・オブ・ケア(POC)分子診断薬市場は、2022年には13億米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年までのCAGR16.3%で、2030年までに10億米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ11%と12.6%の成長が予測されています。欧州では、ドイツがCAGR約12.7%で成長すると予測されています。オーストラリア、インド、韓国などの国々が牽引するアジア太平洋市場は、2030年までに10億米ドルに達すると予測されています。

調査対象企業の例

  • Bayer AG
  • Danaher Corporation
  • DiaSorin SpA
  • Biocartis NV
  • Maxim Biomedical, Inc.
  • AccuBioTech Co., Ltd.
  • Abacus Diagnostica Oy
  • genedrive plc
  • Molbio Diagnostics Pvt. Ltd.
  • Mesa Biotech, Inc.
  • Binx Health
  • Credo Diagnostics Biomedical Pte. Ltd
  • Genestat Molecular Diagnostics, LLC
  • Alveo Technologies
  • ADOR Diagnostics

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
目次
Product Code: MCP22551

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Point of Care (POC) Molecular Diagnostics Market to Reach $8.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Point of Care (POC) Molecular Diagnostics estimated at US$3.2 Billion in the year 2022, is projected to reach a revised size of US$8.8 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. PCR-based, one of the segments analyzed in the report, is projected to record a 14.4% CAGR and reach US$5.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Genetic Sequencing-Based segment is readjusted to a revised 10.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 16.3% CAGR

The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 12.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2030.

Select Competitors (Total 64 Featured) -

  • Bayer AG
  • Danaher Corporation
  • DiaSorin SpA
  • Biocartis NV
  • Maxim Biomedical, Inc.
  • AccuBioTech Co., Ltd.
  • Abacus Diagnostica Oy
  • genedrive plc
  • Molbio Diagnostics Pvt. Ltd.
  • Mesa Biotech, Inc.
  • Binx Health
  • Credo Diagnostics Biomedical Pte. Ltd
  • Genestat Molecular Diagnostics, LLC
  • Alveo Technologies
  • ADOR Diagnostics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
    • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • Pandemic Puts Intense Pressure on Healthcare Systems & Products Worldwide
    • Molecular Diagnostics Receive Healthy Booster from COVID-19 Tests
    • Total Number of COVID-19 Tests Conducted and Tests Per Million Population in Most Impacted Countries: As on September 27, 2021
    • Molecular Point-of-Care Tests for COVID-19 Witness Rapid Growth
    • Molecular RT-PCR Emerges as the Frontline Technology for Testing COVID-19
    • Select Commercial Molecular Tests for COVID-19
    • CRISPR Emerges as Cutting-Edge Biotechnology in COVID-19 Diagnostic Market
    • COVID-19 Affects Demand for Non- COVID Diagnostics
    • Point of Care (POC) Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases
    • Types of Molecular Diagnostics Tests
    • An Introduction to Point of Care (POC) Molecular Diagnostics
    • Molecular Testing Mechanisms
    • Molecular Vs Non-Molecular POCT
    • Global Market Prospects & Outlook
    • PCR Technology Leads the MDx Market
    • Infectious Diseases: The Largest Application Market
    • Reagents and Kits Dominate the Molecular Diagnostics Market
    • Developing Countries Present Strong Growth Prospects
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market
    • Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing
    • Faster Screening Necessitates Point-of-care Diagnostics for COVID-19 Pandemic
    • Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics
    • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
    • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
    • PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
    • Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities
    • Percentage Share Breakdown of Global Deaths Linked to Air Pollution
    • Air Pollution Levels (PM2.5 Concentration (μg/m³) for Major Countries Worldwide for 2020
    • Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2020
    • Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics
    • Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics
    • Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2020
    • Number of AIDS-Related Deaths (in Thousands) by Region for 2018
    • Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
    • Home HIV Testing Emerges as a Lucrative Option
    • Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
    • Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
    • Hepatitis B Prevalence Worldwide by Region
    • Demand Continues to Surge for CLIA-Waived Molecular POC Tests
    • Advancements in POC for Molecular Diagnostics to Drive Market Growth
    • Nanotechnology Facilitates Development of for POC Molecular Diagnostics
    • Healthcare Needs of the World's Aging Population: Potential Opportunity in Store
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050
    • Challenges Facing POC Molecular Diagnostics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for PCR-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Genetic Sequencing-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hybridization-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Microarray-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Decentralized Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 40: World Point of Care (POC) Molecular Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: World 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • FRANCE
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • AUSTRALIA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • INDIA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2023 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2023 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales